RxDoctor Payments Data

Audrey Tashjian, MD

Obstetrics · Lawrenceville, NJNPI 1518939495

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,600 of the $6,002 with a category attached, or 93.3%. Mimedx Group, Inc. accounts for 93.3% of it on its own, with 11 other manufacturers making up the rest. Among obstetrics clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,002in general payments, 2019–2025

Across 38 payments — averaging $157.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$6K
  • Therapeuticsmd, Inc.$129
  • AbbVie$72
  • Pfizer$40
  • Bayer$34
  • Sage Therapeutics, LLC$30
  • plus $97 from 6 others

What the payments were for

  • Consulting fees$5,60093%
  • Food & beverage$3886%
  • Education$140%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,002 in reported general payments places this provider in the 95th percentile of 31 obstetrics providers in New Jersey.

See all obstetrics providers in New Jersey

Medicare billing

Part B allowed, 2024
$24,671
Medicare patients
185
Services billed
544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol193$20,350
PremarinEstrogens, Conjugated30$11,994
EstringEstradiol18$9,186
YuvafemEstradiol49$9,137
Risedronate Sodium11$1,399
Clobetasol Propionate15$769
Raloxifene Hcl17$623
ProgesteroneProgesterone, Micronized13$614
Norethindrone-E.Estradiol-Iron11$66
Fluconazole11$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Estring$40$21,18048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 obstetrics providers in New Jersey.

Other obstetrics in Lawrenceville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →